This biotechnology company is developing bile acid-based therapies that enhance the body's natural mechanisms for regulating bowel function. Their treatments target chronic idiopathic constipation, irritable bowel syndrome with constipation, and other colon-related conditions, including inflammatory bowel disease and metabolic disorders.

Gong provides an AI operating system specifically designed for revenue teams to enhance productivity and predictability. This platform unifies customer insights through its Revenue Graph and delivers actionable intelligence via advanced AI agents. The system automates workflows across platforms, enabling GTM teams to optimize revenue outcomes from prospecting through expansion.

The startup develops targeted therapies for cancer treatment through drug discovery focused on tumor immunology. By enhancing the immune response against tumors, the company aims to improve the quality of life for cancer patients.

Kendall is a first‑party attribution platform for Shopify merchants that consolidates sales, order, and ad‑account data into a single dashboard and applies proprietary attribution logic to assign revenue to the correct campaigns. It provides real‑time performance alerts and actionable recommendations to lower customer acquisition cost and improve ROAS, all for a flat $95 monthly fee regardless of store size.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

Rejuvenate Bio utilizes gene therapy to develop treatments aimed at reversing aging and addressing chronic, age-related diseases that affect six in ten Americans. By targeting the underlying genetic factors of these conditions, the company aims to reduce the prevalence and healthcare costs associated with chronic diseases.

The startup develops TCR gene therapy solutions that provide personalized immunotherapy for cancer patients by engineering T-cell receptors to target specific tumor antigens. This approach enhances treatment efficacy and minimizes side effects compared to traditional therapies.